Briacell Therapeutics Corp BCTX

$4.30 -0.02 (-0.46%)

Valuation

Market cap
37,540,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
169,348
Avg volume
317,190
Day's range
$4.18 – $4.40
Shares out
8,700,000
Stochastic %K
88%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Biotechlineup Sep 28, 11:43 AM
$BCTX Bria Cell is participating in a Renmark Virtual Non-Deal Roadshow Tuesday. Event Details Date, Next Tuesday, September 29, 2026 Time: 2:00 p.m. Eastern Time (11:00 AM PDT) Place, Virtual / Online Webcast Presenters: CEO Dr. William Williams and Jamieson Bondarenko R Renmark Financi... Pre -submit questions for management when signing up. BriaCell's science is highly regarded—their lead asset Bria-IMT received its 7th consecutive positive safety recommendation from the independent Data Safety Monitoring Board (DSMB) for their Phase 3 metastatic breast cancer study. Bctx recently expanded its Phase 3 trial to major institutions like Memorial Sloan Kettering and NYU Langone. We are looking forward to management further confirmation of the trial progress , timeline and cash run . https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-bct-nasdaq-bctx-3BBWyRF7_t
0 replies
2maligators Sep 25, 6:20 PM
$BCTX
0 replies
letsdodiz Sep 25, 3:41 PM
$BCTX If anyone has questions that you want management to answer in the next Tuesdays presentation ask it in the comments when you register for the event.
4 replies
BHWinehouse Sep 25, 10:11 AM
$BCTX Their thought processes for timing of recent (June) financing, 144 events PR announcement, cash runway and partnerships are all discussed here. Still a very worthy watch if you are new here... https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-06-25-11-00-00/index.html
1 replies
mostlyzero Sep 24, 7:40 PM
$BCTX $SLS getting some very thought provoking replies! Love the community feel here! 🥰 lol
1 replies
ZacksResearch Sep 24, 6:42 PM
$BCTX Gains 10.8% in a Month – Will the Momentum Continue? BriaCell’s pivotal Phase 3 Bria-ABC study continues without modifications after the DSMB raised no safety or other clinical concerns. The trial is being conducted under FDA Fast Track designation for metastatic breast cancer. What today’s news means for BCTX investors 👉 https://www.zacks.com/stock/quote/BCTX/detailed-earning-estimates?cid=sm-stocktwits-0-detailed_estimates-oc-39704&ADID=SYND_STOCKTWITS_TWEET_0_DETAILEDESTIMATES_OC_39704
0 replies
mostlyzero Sep 24, 6:24 PM
$BCTX those who’ve been here longer than I have tell me why this can’t become $SLS 2.0? The event driven nature of the trading thesis seems very similar. Strong signal from phase 2. Well designed phase 3. Low float. Not saying the risk profiles are analogous but… SLS: DSMC has already seen unblinded Phase 3 efficacy/futility data and said continue. BCTX: DSMB has repeatedly reviewed Phase 3 safety and said continue, while efficacy remains blinded until the 144-event analysis. I get that early investors have been burned here. But for those of us looking to add now? Beyond murky financing and dilution history, what am I missing from a bear lens?
4 replies
BHWinehouse Sep 24, 6:24 PM
$BCTX
0 replies